Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease

Biochemical and Biophysical Research Communications

Volumn 409, Issue 4, 2011, Pages 651-656

  Chen, Qiang ^a,b   Jiang, Yuan ^a   An, Yuan ^a   Zhao, Na ^a   Zhao, Yang ^a   Yu, Chundong ^a  

^a XIAMEN UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIVERSITY   (China)

Author keywords

Extracellular domain; FGFR4; NAFLD; PPAR

Indexed keywords

ALANINE AMINOTRANSFERASE; BETA ACTIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 4; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; PALMITIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; TETRACYCLINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG INHIBITION; EXPRESSION VECTOR; EXTRACELLULAR MATRIX; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID STORAGE; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; WESTERN BLOTTING;

ANIMALS; CELL LINE, TUMOR; FATTY LIVER; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MICE; MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 4;

EID: 79959265766     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.059     Document Type: Article

References (36)

1. Schlessinger J., Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992, 9:383-391.
2. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A., Linhardt R.J., Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol. Cell 2000, 6:743-750.
3. Eswarakumar V.P., Lax I., Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
4. Ueno H., Gunn M., Dell K., Tseng A., Williams L. A truncated form of fibroblast growth factor receptor 1 inhibits signal transduction by multiple types of fibroblast growth factor receptor. J. Biol. Chem. 1992, 267:1470-1476.
5. Celli G., LaRochelle W.J., Mackem S., Sharp R., Merlino G. Soluble dominant-negative receptor uncovers essential roles for fibroblast growth factors in multi-organ induction and patterning. EMBO J. 1998, 17:1642-1655.
6. Guillonneau X., Regnier-Ricard F., Laplace O., Jonet L., Bryckaert M., Courtois Y., Mascarelli F. Fibroblast growth factor (FGF) soluble receptor 1 acts as a natural inhibitor of FGF2 neurotrophic activity during retinal degeneration. Mol. Biol. Cell 1998, 9:2785-2802.
7. Ezzat S., Zheng L., Yu S., Asa S.L. A soluble dominant negative fibroblast growth factor receptor 4 isoform in human MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 2001, 287:60-65.
8. Kan M., Wu X., Wang F., McKeehan W.L. Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J. Biol. Chem. 1999, 274:15947-15952.
9. Xie M.H., Holcomb I., Deuel B., Dowd P., Huang A., Vagts A., Foster J., Liang J., Brush J., Gu Q., Hillan K., Goddard A., Gurney A.L. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999, 11:729-735.
10. Wright T.J., Ladher R., McWhirter J., Murre C., Schoenwolf G.C., Mansour S.L. Mouse FGF15 is the ortholog of human and chick FGF19, but is not uniquely required for otic induction. Dev. Biol. 2004, 269:264-275.
11. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., Luo G., Jones S.A., Goodwin B., Richardson J.A., Gerard R.D., Repa J.J., Mangelsdorf D.J., Kliewer S.A. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
12. Weinstein M., Xu X., Ohyama K., Deng C.X. FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung. Development 1998, 125:3615-3623.
13. Yu C., Wang F., Kan M., Jin C., Jones R.B., Weinstein M., Deng C.X., McKeehan W.L. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 2000, 275:15482-15489.
14. Huang X., Yang C., Luo Y., Jin C., Wang F., McKeehan W.L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Diabetes 2007, 56:2501-2510.
15. Brunt E.M. Pathology of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7:195-203.
16. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
17. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346:1221-1231.
18. Adams L.A., Lymp J.F., St Sauver J., Sanderson S.O., Lindor K.D., Feldstein A., Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
19. Zhang G., Budker V., Wolff J.A. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 1999, 10:1735-1737.
20. Hart K.C., Robertson S.C., Kanemitsu M.Y., Meyer A.N., Tynan J.A., Donoghue D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19:3309-3320.
21. Holt J.A., Luo G., Billin A.N., Bisi J., McNeill Y.Y., Kozarsky K.F., Donahee M., Wang D.Y., Mansfield T.A., Kliewer S.A., Goodwin B., Jones S.A. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-1591.
22. Chen C., Patel S., Corisdeo S., Liu X., Micolochick H., Xue J., Yang Q., Lei Y., Wang B., Soltis D. Generation and characterization of a panel of monoclonal antibodies specific for human fibroblast growth factor receptor 4 (FGFR4). Hybridoma (Larchmt) 2005, 24:152-159.
23. Malhi H., Bronk S.F., Werneburg N.W., Gores G.J. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J. Biol. Chem. 2006, 281:12093-12101.
24. Gomez-Lechon M.J., Donato M.T., Martinez-Romero A., Jimenez N., Castell J.V., O'Connor J.E. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 2007, 165:106-116.
25. Ricchi M., Odoardi M.R., Carulli L., Anzivino C., Ballestri S., Pinetti A., Fantoni L.I., Marra F., Bertolotti M., Banni S., Lonardo A., Carulli N., Loria P. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J. Gastroenterol. Hepatol. 2009, 24:830-840.
26. Freneaux E., Labbe G., Letteron P., The Le D., Degott C., Geneve J., Larrey D., Pessayre D. Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988, 8:1056-1062.
27. Amacher D.E., Martin B.A. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam. Appl. Toxicol. 1997, 40:256-263.
28. Yu H.Y., Wang B.L., Zhao J., Yao X.M., Gu Y., Li Y. Protective effect of bicyclol on tetracycline-induced fatty liver in mice. Toxicology 2009, 261:112-118.
29. Desnoyers L.R., Pai R., Ferrando R.E., Hotzel K., Le T., Ross J., Carano R., D'Souza A., Qing J., Mohtashemi I., Ashkenazi A., French D.M. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27:85-97.
30. Takayama K., Ueno H., Nakanishi Y., Sakamoto T., Inoue K., Shimizu K., Oohashi H., Hara N. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 2000, 60:2169-2177.
31. Ogawa T., Takayama K., Takakura N., Kitano S., Ueno H. Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor. Cancer Gene Ther. 2002, 9:633-640.
32. Ueno H., Sakamoto T., Nakamura T., Qi Z., Astuchi N., Takeshita A., Shimizu K., Ohashi H. A soluble transforming growth factor beta receptor expressed in muscle prevents liver fibrogenesis and dysfunction in rats. Hum. Gene Ther. 2000, 11:33-42.
33. Krueger G., Callis K. Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch. Dermatol. 2004, 140:218-225.
34. Tobin A.M., Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005, 19:47-57.
35. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J. Biol. Chem. 2006, 281:15694-15700.
36. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature 2000, 405:421-424.